Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.5K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Introduction to Hemostasis01:05

Introduction to Hemostasis

10.6K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
10.6K
Rh Blood Group01:19

Rh Blood Group

2.3K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.4K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

12.2K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
12.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenic implications of translational readthrough modulate the association of F8 nonsense mutations with inhibitors in Hemophilia A.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Italian Patients Journey for Gene Therapy in Haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Plain language summary: a phase 2/3 study of plasminogen, human-tvmh for the treatment of children and adults with type 1 plasminogen deficiency.

Expert review of hematology·2026
Same author

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.

The New England journal of medicine·2026
Same author

Expanding the Toolbox With Non-Factor Therapies.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

United Global Advocacy Drives Updates to World Health Organization Essential Medicines List.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
See all related articles

Related Experiment Video

Updated: Nov 1, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.8K

Haemophilia.

Erik Berntorp1,2, Kathelijn Fischer3, Daniel P Hart4,5

  • 1Department of Translational Medicine, Lund University, Malmö, Sweden. erik.berntorp@med.lu.se.

Nature Reviews. Disease Primers
|June 25, 2021
PubMed
Summary
This summary is machine-generated.

Haemophilia A and B are genetic bleeding disorders. Modern treatments and factor replacement therapy have significantly improved life expectancy and quality of life for patients.

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.7K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.5K

Related Experiment Videos

Last Updated: Nov 1, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.8K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.7K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.5K

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • Haemophilia A and B are rare, X-linked congenital bleeding disorders due to deficiencies in clotting factors VIII (FVIII) or IX (FIX).
  • Disease severity correlates with reduced FVIII or FIX levels, determined by mutations in the F8 and F9 genes.
  • Key clinical features include spontaneous or trauma-induced bleeding into joints (arthropathy), and potentially life-threatening internal or intracranial hemorrhages.

Purpose of the Study:

  • To provide an overview of haemophilia A and B, covering their genetic basis, clinical manifestations, and therapeutic advancements.
  • To highlight the significant improvements in life expectancy and quality of life achieved through modern management strategies.
  • To address current challenges, such as the development of inhibitory antibodies, and discuss future prospects like gene therapy.

Main Methods:

  • Review of existing literature on haemophilia A and B.
  • Analysis of historical and current data on disease progression and treatment outcomes.
  • Examination of advancements in factor replacement therapy and gene therapy.

Main Results:

  • Life expectancy for individuals with haemophilia has dramatically increased from approximately 30 years to a near-normal range.
  • Prophylactic replacement therapy with FVIII or FIX has transformed patient outcomes, enabling a normal quality of life.
  • Inhibitory antibody development remains a significant challenge for a subset of patients undergoing factor replacement therapy.

Conclusions:

  • Significant progress in understanding and treating haemophilia A and B has led to vastly improved patient prognoses.
  • While challenges like inhibitor development persist, gene therapy offers promising future treatment avenues.
  • Continued research and therapeutic innovation are crucial for further enhancing the lives of individuals with haemophilia.